Literature DB >> 20554804

A large study on immunological response to a whole-cell killed oral cholera vaccine reveals that there are significant geographical differences in response and that O blood group individuals do not elicit a higher response.

T Ramamurthy1, Diane Wagener, Goutam Chowdhury, Partha P Majumder.   

Abstract

The ABO blood group system has been implicated in susceptibility to cholera or in explaining variability in the immune response to a cholera vaccine. O blood group individuals were found to be more susceptible to cholera and elicited lower vibriocidal antibody response to cholera toxin B subunit-killed oral vaccine. Based on the observations that O blood group individuals were more susceptible to cholera and that high mortality was associated with cholera, an evolutionary explanation was provided for the extremely low prevalence of the O blood group in the Gangetic Delta (West Bengal, India, and Bangladesh). However, conflicting results were reported from a later study conducted in Indonesia using a live attenuated oral cholera vaccine; O blood group individuals showed a higher vibriocidal antibody response. In a study conducted in a region of India where cholera is endemic (Kolkata, West Bengal) that comprised 992 individuals vaccinated by a killed whole-cell oral cholera vaccine, we found no statistically significant difference between O and non-O individuals either in the frequency distributions of the fold increase or in the postvaccination increase in geometric mean titer compared to the baseline. Further, in contrast to the earlier observation that the O allele frequency is extremely low in the Gangetic Delta, we have noted that the O allele frequency exceeds 0.5 in the vast majority of ethnic groups of this region. In addition, we have found large differences in response to the vaccine among residents of an area where cholera is not endemic compared to an area where cholera is endemic to The percentages of vaccinees who seroconverted in an area where cholera is not endemic (Son La province of Vietnam) was >90% compared to approximately 50% in Kolkata, India, an area where cholera is endemic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554804      PMCID: PMC2916244          DOI: 10.1128/CVI.00123-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  9 in total

1.  ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; M R Khan; S Huda; F Ahmed; J Gomes; M R Rao; A M Svennerholm
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

2.  Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

Authors:  Dang Duc Anh; Do Gia Canh; Anna Lena Lopez; Vu Dinh Thiem; Phan Thi Long; Nguyen Hong Son; Jacqueline Deen; Lorenz von Seidlein; Rodney Carbis; Seung Hyun Han; Seong Hye Shin; Stephen Attridge; Jan Holmgren; John Clemens
Journal:  Vaccine       Date:  2006-09-29       Impact factor: 3.641

3.  Cholera, 2006.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2007-08-03

4.  Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR.

Authors:  P J Cooper; M E Chico; G Losonsky; C Sandoval; I Espinel; R Sridhara; M Aguilar; A Guevara; R H Guderian; M M Levine; G E Griffin; T B Nutman
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

5.  Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity.

Authors:  Jason B Harris; Ashraful I Khan; Regina C LaRocque; David J Dorer; Fahima Chowdhury; Abu S G Faruque; David A Sack; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

6.  Predisposition for cholera of individuals with O blood group. Possible evolutionary significance.

Authors:  R I Glass; J Holmgren; C E Haley; M R Khan; A M Svennerholm; B J Stoll; K M Belayet Hossain; R E Black; M Yunus; D Barua
Journal:  Am J Epidemiol       Date:  1985-06       Impact factor: 4.897

7.  Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.

Authors:  R Lagos; A Avendaño; V Prado; I Horwitz; S Wasserman; G Losonsky; S Cryz; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

8.  Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.

Authors:  A S Benenson; A Saad; W H Mosley
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

9.  A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.

Authors:  Dilip Mahalanabis; Anna Lena Lopez; Dipika Sur; Jacqueline Deen; Byomkesh Manna; Suman Kanungo; Lorenz von Seidlein; Rodney Carbis; Seung Hyun Han; Seong Hye Shin; Stephen Attridge; Raman Rao; Jan Holmgren; John Clemens; Sujit K Bhattacharya
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

  9 in total
  6 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study.

Authors:  Joel G Ray; Alison L Park
Journal:  BMJ Open       Date:  2022-07-18       Impact factor: 3.006

3.  Genomic correlates of variability in immune response to an oral cholera vaccine.

Authors:  Partha P Majumder; Neeta Sarkar-Roy; Herman Staats; T Ramamurthy; Sujit Maiti; Goutam Chowdhury; Carol C Whisnant; K Narayanasamy; Diane K Wagener
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

4.  Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba.

Authors:  Motaher Hossain; Kamrul Islam; Meagan Kelly; Leslie M Mayo Smith; Richelle C Charles; Ana A Weil; Taufiqur Rahman Bhuiyan; Pavol Kováč; Peng Xu; Stephen B Calderwood; Jakub K Simon; Wilbur H Chen; Michael Lock; Caroline E Lyon; Beth D Kirkpatrick; Mitchell Cohen; Myron M Levine; Marc Gurwith; Daniel T Leung; Andrew S Azman; Jason B Harris; Firdausi Qadri; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2019-11-19

Review 5.  Causes of impaired oral vaccine efficacy in developing countries.

Authors:  Edward Pk Parker; Sasirekha Ramani; Benjamin A Lopman; James A Church; Miren Iturriza-Gómara; Andrew J Prendergast; Nicholas C Grassly
Journal:  Future Microbiol       Date:  2017-12-08       Impact factor: 3.165

6.  Gut Microbiota and Development of Vibrio cholerae-Specific Long-Term Memory B Cells in Adults after Whole-Cell Killed Oral Cholera Vaccine.

Authors:  Firdausi Qadri; Ana A Weil; Denise Chac; Taufiqur R Bhuiyan; Amit Saha; Mohammad M Alam; Umme Salma; Nusrat Jahan; Fahima Chowdhury; Ashraful I Khan; Edward T Ryan; Regina LaRocque; Jason B Harris
Journal:  Infect Immun       Date:  2021-08-16       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.